This online course covers different aspects of lipoprotein(a) (Lp(a)): the pathophysiology, its role in CVD risk and (novel) therapeutic options to reduce Lp(a) levels.
Prof. Stroes gives an introduction to the symposium about different aspects of lipoprotein(a) (Lp(a)), that was held during the virtual ESC 2020 congress.
Prof. Bittner summarizes findings from post-hoc analyses of FOURIER and ODYSSEY OUTCOMES on the relationship between Lp(a) lowering by PCSK9 inhibition and CV risk.
RNA therapeutics can reduce production of apo(a) in hepatocyten and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.
High Lp(a) levels are associated with increased risk of CV events. Pia Kamstrup presents the evidence from studies and in addition talks about challenges when determining Lp(a) levels.
Expert discussion on Lp(a), a new lipid frontier in CV risk management & target for therapy.